Impact of Clinical Factors and Treatments on SMARCB1 (INI-1)-Deficient Sinonasal Carcinoma

Kevin J. Contrera; Nasim Shakibai; Shirley Y. Su; Maria K. Gule-Monroe; Dianna Roberts; Bledi Brahimaj; Michelle D. Williams; Renata Ferrarotto; Jack Phan; Brandon Gunn; Shaan Raza; Franco DeMonte; Ehab Y. Hanna

doi:10.1002/ohn.310

Impact of Clinical Factors and Treatments on SMARCB1 (INI-1)-Deficient Sinonasal Carcinoma

Kevin J. Contrera, Nasim Shakibai, Shirley Y. Su, Maria K. Gule-Monroe, Dianna Roberts, Bledi Brahimaj, Michelle D. Williams, Renata Ferrarotto, Jack Phan, Brandon Gunn, Shaan Raza, Franco DeMonte, Ehab Y. Hanna

Research output: Contribution to journal › Article › peer-review

3 Scopus citations

Abstract

The objective of this study was to report outcomes for 19 consecutive patients with SMARCB1 (INI-1)-deficient sinonasal carcinoma. Patients were treated from 2014 to 2021 and followed for a median of 22.3 months. The median overall survival (OS) and disease-free survival (DFS) were 31.8 and 9.9 months, respectively. Patients with nasal cavity or maxillary sinus tumors had 84% better disease-specific survival (DSS) (hazard ratio [HR], 0.136; 95% confidence interval [CI], 0.028-0.66; p =.005) and 71% better DFS (HR, 0.29; 95% CI, 0.097-0.84; p =.041) than patients with other sinonasal sites. Patients who received induction chemotherapy were 76% less likely to die of disease (DSS HR, 0.241; 95% CI, 0.058-1.00; p =.047). In the largest single-institution study of SMARCB1-deficient sinonasal carcinoma to date, OS and DFS approached 3 years and 1 year, respectively, but were better for nasal cavity and maxillary sinus tumors. Patients may benefit from induction chemotherapy.

Original language	English (US)
Pages (from-to)	435-440
Number of pages	6
Journal	Otolaryngology - Head and Neck Surgery (United States)
Volume	169
Issue number	2
DOIs	https://doi.org/10.1002/ohn.310
State	Published - Aug 2023

Keywords

carcinoma
induction chemotherapy
INI-1
sinonasal
SMARCB1

ASJC Scopus subject areas

Surgery
Otorhinolaryngology

Access to Document

10.1002/ohn.310

Cite this

Contrera, K. J., Shakibai, N., Su, S. Y., Gule-Monroe, M. K., Roberts, D., Brahimaj, B., Williams, M. D., Ferrarotto, R., Phan, J., Gunn, B., Raza, S., DeMonte, F., & Hanna, E. Y. (2023). Impact of Clinical Factors and Treatments on SMARCB1 (INI-1)-Deficient Sinonasal Carcinoma. Otolaryngology - Head and Neck Surgery (United States), 169(2), 435-440. https://doi.org/10.1002/ohn.310

Contrera, KJ, Shakibai, N, Su, SY , Gule-Monroe, MK, Roberts, D, Brahimaj, B, Williams, MD , Ferrarotto, R , Phan, J , Gunn, B , Raza, S , DeMonte, F & Hanna, EY 2023, 'Impact of Clinical Factors and Treatments on SMARCB1 (INI-1)-Deficient Sinonasal Carcinoma', Otolaryngology - Head and Neck Surgery (United States), vol. 169, no. 2, pp. 435-440. https://doi.org/10.1002/ohn.310

@article{bb74f133c7de4faebd5b9e49749f7669,

title = "Impact of Clinical Factors and Treatments on SMARCB1 (INI-1)-Deficient Sinonasal Carcinoma",

abstract = "The objective of this study was to report outcomes for 19 consecutive patients with SMARCB1 (INI-1)-deficient sinonasal carcinoma. Patients were treated from 2014 to 2021 and followed for a median of 22.3 months. The median overall survival (OS) and disease-free survival (DFS) were 31.8 and 9.9 months, respectively. Patients with nasal cavity or maxillary sinus tumors had 84% better disease-specific survival (DSS) (hazard ratio [HR], 0.136; 95% confidence interval [CI], 0.028-0.66; p =.005) and 71% better DFS (HR, 0.29; 95% CI, 0.097-0.84; p =.041) than patients with other sinonasal sites. Patients who received induction chemotherapy were 76% less likely to die of disease (DSS HR, 0.241; 95% CI, 0.058-1.00; p =.047). In the largest single-institution study of SMARCB1-deficient sinonasal carcinoma to date, OS and DFS approached 3 years and 1 year, respectively, but were better for nasal cavity and maxillary sinus tumors. Patients may benefit from induction chemotherapy.",

keywords = "carcinoma, induction chemotherapy, INI-1, sinonasal, SMARCB1",

author = "Contrera, {Kevin J.} and Nasim Shakibai and Su, {Shirley Y.} and Gule-Monroe, {Maria K.} and Dianna Roberts and Bledi Brahimaj and Williams, {Michelle D.} and Renata Ferrarotto and Jack Phan and Brandon Gunn and Shaan Raza and Franco DeMonte and Hanna, {Ehab Y.}",

note = "Funding Information: The authors would like to thank Bryan Tutt, Scientific Editor, Research Medical Library, for the editorial support. Publisher Copyright: {\textcopyright} 2023 American Academy of Otolaryngology–Head and Neck Surgery Foundation.",

year = "2023",

month = aug,

doi = "10.1002/ohn.310",

language = "English (US)",

volume = "169",

pages = "435--440",

journal = "Otolaryngology - Head and Neck Surgery (United States)",

issn = "0194-5998",

publisher = "Mosby Inc.",

number = "2",

}

TY - JOUR

T1 - Impact of Clinical Factors and Treatments on SMARCB1 (INI-1)-Deficient Sinonasal Carcinoma

AU - Contrera, Kevin J.

AU - Shakibai, Nasim

AU - Su, Shirley Y.

AU - Gule-Monroe, Maria K.

AU - Roberts, Dianna

AU - Brahimaj, Bledi

AU - Williams, Michelle D.

AU - Ferrarotto, Renata

AU - Phan, Jack

AU - Gunn, Brandon

AU - Raza, Shaan

AU - DeMonte, Franco

AU - Hanna, Ehab Y.

N1 - Funding Information: The authors would like to thank Bryan Tutt, Scientific Editor, Research Medical Library, for the editorial support. Publisher Copyright: © 2023 American Academy of Otolaryngology–Head and Neck Surgery Foundation.

PY - 2023/8

Y1 - 2023/8

N2 - The objective of this study was to report outcomes for 19 consecutive patients with SMARCB1 (INI-1)-deficient sinonasal carcinoma. Patients were treated from 2014 to 2021 and followed for a median of 22.3 months. The median overall survival (OS) and disease-free survival (DFS) were 31.8 and 9.9 months, respectively. Patients with nasal cavity or maxillary sinus tumors had 84% better disease-specific survival (DSS) (hazard ratio [HR], 0.136; 95% confidence interval [CI], 0.028-0.66; p =.005) and 71% better DFS (HR, 0.29; 95% CI, 0.097-0.84; p =.041) than patients with other sinonasal sites. Patients who received induction chemotherapy were 76% less likely to die of disease (DSS HR, 0.241; 95% CI, 0.058-1.00; p =.047). In the largest single-institution study of SMARCB1-deficient sinonasal carcinoma to date, OS and DFS approached 3 years and 1 year, respectively, but were better for nasal cavity and maxillary sinus tumors. Patients may benefit from induction chemotherapy.

AB - The objective of this study was to report outcomes for 19 consecutive patients with SMARCB1 (INI-1)-deficient sinonasal carcinoma. Patients were treated from 2014 to 2021 and followed for a median of 22.3 months. The median overall survival (OS) and disease-free survival (DFS) were 31.8 and 9.9 months, respectively. Patients with nasal cavity or maxillary sinus tumors had 84% better disease-specific survival (DSS) (hazard ratio [HR], 0.136; 95% confidence interval [CI], 0.028-0.66; p =.005) and 71% better DFS (HR, 0.29; 95% CI, 0.097-0.84; p =.041) than patients with other sinonasal sites. Patients who received induction chemotherapy were 76% less likely to die of disease (DSS HR, 0.241; 95% CI, 0.058-1.00; p =.047). In the largest single-institution study of SMARCB1-deficient sinonasal carcinoma to date, OS and DFS approached 3 years and 1 year, respectively, but were better for nasal cavity and maxillary sinus tumors. Patients may benefit from induction chemotherapy.

KW - carcinoma

KW - induction chemotherapy

KW - INI-1

KW - sinonasal

KW - SMARCB1

UR - http://www.scopus.com/inward/record.url?scp=85150198811&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85150198811&partnerID=8YFLogxK

U2 - 10.1002/ohn.310

DO - 10.1002/ohn.310

M3 - Article

C2 - 36856048

AN - SCOPUS:85150198811

SN - 0194-5998

VL - 169

SP - 435

EP - 440

JO - Otolaryngology - Head and Neck Surgery (United States)

JF - Otolaryngology - Head and Neck Surgery (United States)

IS - 2

ER -

Impact of Clinical Factors and Treatments on SMARCB1 (INI-1)-Deficient Sinonasal Carcinoma

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this